Maillard Reaction Products in the Escherichia coliderived Therapeutic Protein Interferon Alfacon-1
We have recently shown that recombinant human interferon-? is affected by early stages of the Maillard reaction during its production in Escherichia coli. Over time, advanced glycation end products accumulated in the purified protein, accompanied with degradation, cross-linking, and a drop in the protein's biologic activity. Here, we provide further evidence for the presence of Maillard reaction products in another E. coliderived therapeutic protein, interferon alfacon-1. These products might interfere with both treatment efficacy and patient safety.
maillard reaction interferon alfacon-1 advanced glycation end products glycation consensus interferon antidrug antibodies adverse events